Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder

Inclusion Criteria: * Diagnosis of asthma as defined by Global Initiative for Asthma (GINA) 2011 * Asthmatic patients already treated with low daily doses of Inhaled Corticosteroids (ICS) (eg budesonide or equivalent lower than 400 mcg/day) or low dose of ICS/Long Acting Beta2 Agonists (LABA) fixed combinations. * Patients with Forced Expiratory Volume in 1 sec (FEV1) \>= 70 % of predicted values * Non or ex-smokers * Body Mass Index (BMI) \>= 18.5 and \<= 32 kg/m2 Exclusion Criteria: * Pregnant or lactating women unless using acceptable methods of contraception * Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) * History of near fatal asthma * Patients with abnormal QTcF at screening Visit * Hospitalization due to asthma exacerbation within 4 weeks prior to the screening visit or during the run-in period. * Lower respiratory tract infection within 4 weeks prior to the screening visit or during the run-in period. * History of drug addiction or excessive use of alcohol ; * Diagnosis of restrictive lung disease. * Patients treated with oral or parenteral corticosteroids in the previous 2 months before the screening visit (3 months for parenteral depot corticosteroids) * Significant medical history or any laboratory abnormality indicative of a significant underlying condition